Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheridan

Showing results (81-90 of 7,539) with videos related to

Pageof 754
Sort By:
Nature Biotechnology|April 14, 2025
Not just obesity: GLP-1 receptor agonists advance on addictionCormac Sheridan
Nature Biotechnology|November 8, 2022
For hemophilia and thalassemia, a new era of 'one-and-done' gene therapies has arrivedCormac Sheridan
Medical Device Technology|April 25, 2001
Self-preservation in the face of regulatory adversityB Sheridan
Geriatrics|May 1, 1976
Restoring speech and language skillsJ Sheridan
Brain, Behavior, and Immunity|April 12, 2003
The HPA axis, SNS, and immunity: a commentaryJohn Sheridan
Nature Biotechnology|March 8, 2019
Publisher Correction: Death by inflammation: drug makers chase the master controllerCormac Sheridan
Journal of Nursing Staff Development : JNSD|January 1, 1988
Definition and selection of nursing rolesM Sheridan
Nature Biotechnology|February 5, 2021
Publisher Correction: First small-molecule drug targeting RNA gains momentumCormac Sheridan
Nature Biotechnology|September 10, 2011
Drugmakers use real-world patient data to calibrate product developmentCormac Sheridan
Journal of Cataract and Refractive Surgery|April 24, 2012
Optimized constants for an ultraviolet light-adjustable intraocular lensSheridan Lam
Pageof 754

Showing results (81-90 of 7,539) with videos related to

Sort By:
Pageof 754
Nature Biotechnology|April 14, 2025
Not just obesity: GLP-1 receptor agonists advance on addictionCormac Sheridan
Nature Biotechnology|November 8, 2022
For hemophilia and thalassemia, a new era of 'one-and-done' gene therapies has arrivedCormac Sheridan
Medical Device Technology|April 25, 2001
Self-preservation in the face of regulatory adversityB Sheridan
Geriatrics|May 1, 1976
Restoring speech and language skillsJ Sheridan
Brain, Behavior, and Immunity|April 12, 2003
The HPA axis, SNS, and immunity: a commentaryJohn Sheridan
Nature Biotechnology|March 8, 2019
Publisher Correction: Death by inflammation: drug makers chase the master controllerCormac Sheridan
Journal of Nursing Staff Development : JNSD|January 1, 1988
Definition and selection of nursing rolesM Sheridan
Nature Biotechnology|February 5, 2021
Publisher Correction: First small-molecule drug targeting RNA gains momentumCormac Sheridan
Nature Biotechnology|September 10, 2011
Drugmakers use real-world patient data to calibrate product developmentCormac Sheridan
Journal of Cataract and Refractive Surgery|April 24, 2012
Optimized constants for an ultraviolet light-adjustable intraocular lensSheridan Lam
Pageof 754